SLC3A2 and malignant colon neoplasm: This suggests that SLC3A2 can serve as a receptor for targeted drug delivery in colon cancer cells and that its downregulation, in combination with anticancer drug treatment, increases the therapeutic efficacy of the anticancer drug.